RCT: Omega‐3 fatty acids not supported as adjunct therapy for pediatric depression

Alison Knopf

doi:10.1002/cpu.31037

February 1, 2026The Brown University Child & Adolescent Psychopharmacology Update

RCT: Omega‐3 fatty acids not supported as adjunct therapy for pediatric depression

View at Publisher

Ask AI

Bookmark

Share

Key Points

To evaluate the effectiveness of omega-3 fatty acids as an adjunct therapy in children and adolescents with major depressive disorder.
Conducted a randomized clinical trial (RCT) with a pediatric population.
Administered omega-3 fatty acids (EPA and DHA) along with antidepressants.
Compared the omega-3 treatment group to a placebo group.
Omega-3 fatty acids did not show significant improvement over placebo in treating major depressive disorder.
No substantial differences in depressive symptoms reported between the two groups.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

RCT assesses omega-3 fatty acids as adjunct therapy for pediatric depression, suggesting limited efficacy.

Abstract

A randomized clinical trial (RCT) of children and adolescents found that omega‐3 fatty acids such as EPA and DHA, as an adjunct to antidepressants, did not outperform placebo in youths with major depressive disorder (MDD).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Alison Knopf (2026) studied this question.

synapsesocial.com/papers/699a9ded482488d673cd4444 https://doi.org/10.1002/cpu.31037

View at Publisher

Ask AI

Bookmark

Share

RCT: Omega‐3 fatty acids not supported as adjunct therapy for pediatric depression

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

RCT: Omega‐3 fatty acids not supported as adjunct therapy for pediatric depression

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading